tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Thomas Wei, 3 are a SELL (10.71%), 1 are a HOLD (3.57%), 24 are a BUY (85.71%).
Analyst Thomas Wei, carries an average stock price target met ratio of 84.62% that have a potential upside of 51.93% achieved within 452 days. Previously, Thomas Wei worked at JEFFERIES.
Thomas Wei’s has documented 73 price targets and ratings displayed on 14 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on FWP, Forward Pharma A S at 20-Apr-2015.
Analyst best performing recommendations are on NBIX (NEUROCRINE BIOSCIENCES).
The best stock recommendation documented was for ACAD (ACADIA PHARMACEUTICALS) at 5/6/2013. The price target of $18 was fulfilled within 35 days with a profit of $5.82 (47.78%) receiving and performance score of 13.65.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Sell Since 06-Jun-2022
$13
$1.68 (14.84%)
2 months ago
(21-Aug-2026)
2/4 (50%)
$-1.09 (-7.74%)
170
Hold Since 19-Oct-2022
$12
$-3.91 (-24.58%)
$800
11 months 21 days ago
(30-Oct-2025)
2/4 (50%)
$-4.4 (-26.83%)
1055
Sell Since 03-Nov-2021
$12
$0.68 (6.01%)
$20
1 years 3 months 26 days ago
(25-Jun-2025)
10/14 (71.43%)
$-4.19 (-25.88%)
92
Buy Since 05-Mar-2021
$100
2 years 4 months 1 days ago
(20-Jun-2024)
12/56 (21.43%)
$62.4 (165.96%)
171
Buy Since 25-Oct-2023
$20
$8.68 (76.68%)
$60
2 years 11 months 26 days ago
(25-Oct-2023)
5/26 (19.23%)
$5.72 (40.06%)
73
